Lori Anne Kunkel
CIK: 0001536368
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (17 total)
- Oct 30, 2026ELVN
Enliven Therapeutics, Inc.
Exercise(M)Direct7.3K shares at avg. $18.30$134K - Oct 30, 2026ELVN
Enliven Therapeutics, Inc.
Exercise(M)Direct3.7K shares at avg. $1.12$4K - Jul 6, 2026ELVN
Enliven Therapeutics, Inc.
Sale(S)Direct4.1K shares at avg. $49.98$205K - Jul 6, 2026ELVN
Enliven Therapeutics, Inc.
Sale(S)Direct5.9K shares at avg. $50.84$299K - Jun 5, 2026ELVN
Enliven Therapeutics, Inc.
Sale(S)Direct7.8K shares at avg. $34.28$267K - Jun 5, 2026ELVN
Enliven Therapeutics, Inc.
Sale(S)Direct1.9K shares at avg. $35.36$66K - Jun 5, 2026ELVN
Enliven Therapeutics, Inc.
Sale(S)Direct354 shares at avg. $35.82$13K - Feb 12, 2026ELVN
Enliven Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
17.1K shares- - Jan 2, 2026ORIC
Oric Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
40K shares- - Dec 17, 2025ELVN
Enliven Therapeutics, Inc.
Exercise(M)Direct16K shares at avg. $1.12$18K - Dec 8, 2025ORIC
Oric Pharmaceuticals, Inc.
Exercise(M)Direct10K shares at avg. $7.90$79K - Dec 4, 2025ORIC
Oric Pharmaceuticals, Inc.
Exercise(M)Direct5.5K shares at avg. $3.75$21K - May 19, 2025NRIX
Nurix Therapeutics, Inc.
Award(A)DirectDirector Stock Option (right to buy)
25K shares- - Mar 3, 2025ORIC
Oric Pharmaceuticals, Inc.
Exercise(M)Direct20.5K shares at avg. $6.33$130K - Mar 3, 2025ORIC
Oric Pharmaceuticals, Inc.
Exercise(M)Direct27.7K shares at avg. $3.75$104K - Feb 6, 2025ELVN
Enliven Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
15.4K shares- - Jan 2, 2025ORIC
Oric Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
35K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 30, 2026 |  ELVN Enliven Therapeutics, Inc. | Exercise(M) | 7,300 | $18.30 | $133,590 | Direct |
| Oct 30, 2026 | ELVN Enliven Therapeutics, Inc. | Exercise(M) | 3,741 | $1.12 | $4,190 | Direct |
| Jul 6, 2026 | ELVN Enliven Therapeutics, Inc. | Sale(S) | 4,111 | $49.98 | $205,482 | Direct |
| Jul 6, 2026 | ELVN Enliven Therapeutics, Inc. | Sale(S) | 5,889 | $50.84 | $299,421 | Direct |
| Jun 5, 2026 | ELVN Enliven Therapeutics, Inc. | Sale(S) | 7,779 | $34.28 | $266,659 | Direct |
| Jun 5, 2026 | ELVN Enliven Therapeutics, Inc. | Sale(S) | 1,867 | $35.36 | $66,012 | Direct |
| Jun 5, 2026 | ELVN Enliven Therapeutics, Inc. | Sale(S) | 354 | $35.82 | $12,680 | Direct |
| Feb 12, 2026 | ELVN Enliven Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 17,126 | - | - | Direct |
| Jan 2, 2026 |  ORIC Oric Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 40,000 | - | - | Direct |
| Dec 17, 2025 | ELVN Enliven Therapeutics, Inc. | Exercise(M) | 15,958 | $1.12 | $17,873 | Direct |
| Dec 8, 2025 | ORIC Oric Pharmaceuticals, Inc. | Exercise(M) | 10,000 | $7.90 | $79,000 | Direct |
| Dec 4, 2025 | ORIC Oric Pharmaceuticals, Inc. | Exercise(M) | 5,534 | $3.75 | $20,753 | Direct |
| May 19, 2025 |  NRIX Nurix Therapeutics, Inc. | Award(A) Director Stock Option (right to buy) | 25,000 | - | - | Direct |
| Mar 3, 2025 | ORIC Oric Pharmaceuticals, Inc. | Exercise(M) | 20,500 | $6.33 | $129,765 | Direct |
| Mar 3, 2025 | ORIC Oric Pharmaceuticals, Inc. | Exercise(M) | 27,666 | $3.75 | $103,748 | Direct |
| Feb 6, 2025 | ELVN Enliven Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 15,368 | - | - | Direct |
| Jan 2, 2025 | ORIC Oric Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 35,000 | - | - | Direct |
1-17 of 17 transactions
About Kunkel Lori Anne
Kunkel Lori Anne (SEC CIK 0001536368) files insider reports with the SEC as Enliven Therapeutics, Inc. (ELVN), Director of Oric Pharmaceuticals, Inc. (ORIC) and Director of Nurix Therapeutics, Inc. (NRIX).
Signal8 holds 12 ownership filings by Kunkel Lori Anne, all Form 4s, filed between Jan 6, 2025 and Nov 3, 2026. Those filings report 17 transactions, from Jan 2, 2025 to Oct 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kunkel Lori Anne's filings is in BURLINGAME, CA.
Recent filings by Kunkel Lori Anne
- Oct 30, 2026: Option exercises of ELVN shares (2 lines, Form 4, code M).
- Jul 6, 2026: Open-market sales of ELVN shares (2 lines, Form 4, code S).
- Jun 5, 2026: Open-market sales of ELVN shares (3 lines, Form 4, code S).
- Feb 12, 2026: Grant or award of ELVN derivative securities (Form 4, code A).
- Jan 2, 2026: Grant or award of ORIC derivative securities (Form 4, code A).
Other insiders filing for Enliven Therapeutics, Inc. (ELVN)
- Hohl Benjamin, CHIEF FINANCIAL OFFICER
- Collins Helen Louise, CHIEF MEDICAL OFFICER
- BALL KRISTINE M, Director
- Garland J. Scott, Director
- Derynck Mika K, Director
- ORBIMED ADVISORS LLC, 10% Owner